Sort
48,018 grants matching “immunotherapy”
Persistent STAT5 signaling in polyfunctional CD4 T cells and its application in adoptive T cell therapy
$496,606Gang Zhou · Augusta University · R01 · FY2024 · CA
Mechanisms of Lymphomagenesis of Skin Resident Gamma Delta T cells
$496,574Isabelle Caroline Le Poole · Northwestern University At Chicago · R01 · FY2025 · CA
Computational tumor phenotyping to interrogate treatment resistance and immune dysregulation in head and neck cancer
$496,567Kyle Lafata · Duke University · R01 · FY2024 · CA
Interactions between the tumor cells and the neuro-immune microenvironment in mutant IDH1 gliomas: implications for therapeutics
$496,508Maria G Castro · University Of Michigan At Ann Arbor · R01 · FY2021 · NS
Chemical probes for imaging and treatment of otitis media
$496,496Matthew S Bogyo · Stanford University · R01 · FY2025 · EB
Mitochondrial NAD+ in Acute Myeloid Leukemias
$496,412Xiaolu Ang Cambronne · University Of Texas At Austin · R01 · FY2024 · CA
Manipulating Lipid Metabolism to Reverse Immune Dysfunction in Solid Cancers
$496,391Jessica E Thaxton · Univ Of North Carolina Chapel Hill · R01 · FY2025 · CA
TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer
$496,381Gerardo Guillermo Mackenzie · University Of California At Davis · R01 · FY2024 · CA
Phosphorylation of TSC2 (S1365) as a novel Regulator of mTORC1 Signaling in T Cells
$496,376Erika L Pearce · Johns Hopkins University · R01 · FY2025 · AI
Role of Tim-3:Bat-3 pathway in inducing tolerogenic DCs and peripheral tolerance
$496,340Vijay K Kuchroo · Brigham And Women'S Hospital · R01 · FY2025 · AI
TOWARD TRANSLATION OF NANFORMULATED PACLITAXEL-PLATINUM COMBINATION
$496,337Alexander V Kabanov · Univ Of North Carolina Chapel Hill · R01 · FY2023 · CA
Tumor Growth and Microenvironment Influence T Cell Tolerance to Tumor Antigens
$496,305Arthur Hurwitz · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
In Vitro Approach To Problems of Clinical Allergy
$496,270Johns Hopkins University · R01 · FY2002 · AI
Chitinase-3-like-1 mediated immunosuppression in Glioblastoma
$496,239Baoli Hu · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · CA
Cell-targeted glutamine antagonists as a novel therapy for lymphoma
$496,172Barbara Stauch Slusher · Johns Hopkins University · R01 · FY2021 · CA
Project 1: Transgenic TCR-mediated tumor therapy
$496,050Philip D Greenberg · University Of Washington · P01 · FY2019 · CA
Transplant EBV Disease: Pathogenesis and Immunotherapy
$496,006University Of Pittsburgh At Pittsburgh · P50 · FY2004 · HL
Predict radiation-induced shifts in patient-specific tumor immune ecosystem composition to harness immunological consequences of radiotherapy
$495,971Heiko Enderling · H. Lee Moffitt Cancer Ctr & Res Inst · U01 · FY2020 · CA
Generating CTL Against Tumor Associated Peptide Antigens
$495,899Linda A Sherman · Scripps Research Institute, The · R01 · FY2006 · CA
Modulation of Inflammatory Responses by Helminth Glycans
$495,849Richard D Cummings · Beth Israel Deaconess Medical Center · R01 · FY2017 · AI
A Therapeutic Vaccine for EBV-Associated Malignancies
$495,848Paul M. Lieberman · Wistar Institute · RC2 · FY2009 · CA
Role of Tspan5 in MHC I antigen presentation and cancer immune evasion
$495,793Kenneth L Rock · Univ Of Massachusetts Med Sch Worcester · R01 · FY2023 · AI
BBB Protection in HIV Infection: Barrier-shielding effects of PARP inhibition
$495,775Yuri Persidsky · Temple Univ Of The Commonwealth · R01 · FY2012 · MH
Gonorrhea and HIV prevention with intravaginal ring drug delivery
$495,740Sanjay Ram · Univ Of Massachusetts Med Sch Worcester · R61 · FY2019 · AI
Dissecting the role of Notch signaling in the pancreatic cancer microenvironment.
$495,740Marina Pasca Di Magliano · University Of Michigan At Ann Arbor · R01 · FY2024 · CA